TENAX THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On January 4, 2022, Tenax Therapeutics, Inc. issued a press release announcing updates on its TNX-102 (subcutaneous levosimendan), TNX-103 (oral levosimendan) and TNX-201 (oral imatinib mesylate) clinical programs. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits




Exhibit
  No.      Description
  99.1       Press Release dated January 4, 2022.

104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document).





2

© Edgar Online, source Glimpses